Maykin Ho - PAREXEL International Director

Dr. Maykin Ho Ph.D. is an Independent Director of the Company. She is a member of the Audit and Finance Committee
Age: 63  Director Since 2015  Ph.D    
781 487-9900
Ho was a venture partner of Qiming Venture Partners, a VC firm in China and Hong Kong, since July 2015. From July 1992 to February 2015, she held various positions at Goldman Sachs, a global investment bank, including: from 2010 to 2015, she served as Advisory Director of Global Healthcare Investment Banking; from 2002 to 2010, she served as Partner and CoHead of Healthcare Investment Research; and from 1992 to 2010 she served as Senior Biotechnology Research Analyst. Prior to joining Goldman Sachs, Dr. Ho was the Director of Strategic Planning and Licensing for Du Pont Merck Pharmaceutical Company. She currently also serves on the Board of Directors of Agios Pharmaceuticals.

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Louise ParentZoetis
David BullockOrigin Agritech Limited
Bruce SachsVertex Pharmaceuticals Incorpor
Fei WangOrigin Agritech Limited
Bruce CarterDr Reddys Laboratories Ltd
Michael JandernoaPerrigo Company Plc
Michael TrimbleOrigin Agritech Limited
Adriana KaraboutisPerrigo Company Plc
Gary KunklePerrigo Company Plc
Marc TessierLavigneRegeneron Pharmaceuticals
Prasad MenonDr Reddys Laboratories Ltd
Lloyd CarneyVertex Pharmaceuticals Incorpor
Terrence KearneyVertex Pharmaceuticals Incorpor
James KangOrigin Agritech Limited
Yingqi XiaOrigin Agritech Limited
Ashok GangulyDr Reddys Laboratories Ltd
Leo PuriDr Reddys Laboratories Ltd
Anupam PuriDr Reddys Laboratories Ltd
Huda ZoghbiRegeneron Pharmaceuticals
Elaine UllianVertex Pharmaceuticals Incorpor
Kalpana MorpariaDr Reddys Laboratories Ltd

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Did you try this?

Run Money Flow Index Now


Money Flow Index

Determine momentum by analyzing Money Flow Index and other technical indicators
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 200 shares of
a day ago
Traded for 14.76
Purchased over 50 shares of
a day ago
Traded for 53.37
Purchased few shares of
a day ago
Traded for 270.71
Purchased over 40 shares of
a day ago
Traded for 75.81
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.